JNCE Jounce Therapeutics, Inc.

16.99
-0.45  -3%
Previous Close 17.44
Open 17.39
Price To book 3.15
Market Cap 545.96M
Shares 32,134,000
Volume 79,008
Short Ratio 5.57
Av. Daily Volume 147,342

SEC filingsSee all SEC filings

  1. 8-K - Current report 17863103
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825686
  3. 8-K - Current report 17824747
  4. 8-K - Current report 17773158
  5. 8-K - Current report 17732245

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated September 2017.Phase 2 arm initiation announced April 21, 2017. Efficacy data due end of 2017. Phase 1 safety data released at ASCO June 2017.
JTX-2011
Solid tumors - Cancer

Latest News

  1. Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
  2. 3 Top Healthcare Stocks You Haven't Thought Of
  3. OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.
  4. Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting
  5. Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : May 19, 2017
  6. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : May 18, 2017
  7. Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
  8. Jounce Therapeutics Reports First Quarter 2017 Financial Results
  9. Will Jounce Therapeutics (JNCE) Continue to Surge Higher?
  10. Merck KGaA says dominance in liquid crystals could be at risk
  11. Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
  12. Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : April 14, 2017
  13. Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
  14. New ​Cambridge-based, Third Rock-backed biotech revealed in federal filing
  15. Lexington's Agenus quietly discloses failure of cancer vaccine trial
  16. ​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash
  17. Robust Start for Pharmaceutical IPOs In 2017